---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310670"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:03:06.258778+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call

## Summary
- Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.
- Specific efficacy, safety, and biomarker outcomes not available from provided text.
- Conference call hosted by CEO Nello Mainolfi and CMO Jared Gollob.
- KT-621 is first-in-class oral STAT6 degrader targeting Th2-driven inflammation.

## SEC filing metadata
- accession: 0001193125-25-310670
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/0001193125-25-310670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310670
- JSON: https://secwatch.observer/filing/0001193125-25-310670.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.